Syncona leads CHF35 million A round for Anaveon

Anaveon AG (Zurich, Switzerland) closed the first undisclosed tranche of a CHF35 million ($35 million) series A round Tuesday to help bring its biologic IL-2 receptor agonists into the clinic. Syncona Ltd.

Read the full 328 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE